Elma Meershoek-Klein Kranenbarg
Overview
Explore the profile of Elma Meershoek-Klein Kranenbarg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
72
Citations
3938
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Bahadoer R, Hospers G, Marijnen C, Peeters K, Putter H, Dijkstra E, et al.
Eur J Cancer
. 2023 Mar;
185:139-149.
PMID: 36996624
Introduction: Although optimising rectal cancer treatment has reduced local recurrence rates, many patients develop distant metastases (DM). The current study investigated whether a total neoadjuvant treatment strategy influences the development,...
12.
Temmink S, Peeters K, Bahadoer R, Meershoek-Klein Kranenbarg E, Roodvoets A, Melenhorst J, et al.
Br J Surg
. 2023 Mar;
110(6):676-684.
PMID: 36972213
Background: In rectal cancer, watch and wait for patients with a cCR after neoadjuvant treatment has an established evidence base. However, there is a lack of consensus on the definition...
13.
Dijkstra E, Nilsson P, Hospers G, Bahadoer R, Meershoek-Klein Kranenbarg E, Roodvoets A, et al.
Ann Surg
. 2023 Jan;
278(4):e766-e772.
PMID: 36661037
Objective: To analyze risk and patterns of locoregional failure (LRF) in patients of the RAPIDO trial at 5 years. Background: Multimodality treatment improves local control in rectal cancer. Total neoadjuvant...
14.
Fernandez L, Sao Juliao G, Renehan A, Beets G, Papoila A, Vailati B, et al.
Dis Colon Rectum
. 2022 Dec;
66(1):41-49.
PMID: 36515514
Background: Nearly 30% of patients with rectal cancer develop local regrowth after initial clinical complete response managed by watch and wait. These patients might be at higher risk for distant...
15.
Hagenaars S, Dekker L, Ravesteijn B, van Vlierberghe R, Romijn F, Verhoeff L, et al.
Int J Mol Sci
. 2022 Oct;
23(20).
PMID: 36293255
The prospective, multicenter TESTBREAST study was initiated with the aim of identifying a novel panel of blood-based protein biomarkers to enable early breast cancer detection for moderate-to-high-risk women. Serum samples...
16.
van Kooten R, Elske van den Akker-Marle M, Putter H, Meershoek-Klein Kranenbarg E, van de Velde C, Wouters M, et al.
Clin Colorectal Cancer
. 2022 Oct;
21(4):325-338.
PMID: 36210321
Background: Survival for rectal cancer patients has improved over the past decades. In parallel, long-term health-related quality of life (HRQoL) is gaining interest. This study focuses on the effect of...
17.
Slagter A, Caspers I, van Grieken N, Walraven I, Lind P, Meershoek-Klein Kranenbarg E, et al.
Cancers (Basel)
. 2022 Jun;
14(12).
PMID: 35740628
(1) Background: Perioperative chemotherapy is the current standard treatment for patients with resectable gastric cancer. Based on studies in patients with metastatic gastric cancer, oxaliplatin has replaced cisplatin in the...
18.
Esgueva A, Noordhoek I, Meershoek-Klein Kranenbarg E, Espinosa-Bravo M, Matrai Z, Zhygulin A, et al.
Ann Surg Oncol
. 2022 Apr;
29(9):5828.
PMID: 35486268
No abstract available.
19.
Dijkstra E, Hospers G, Meershoek-Klein Kranenbarg E, Fleer J, Roodvoets A, Bahadoer R, et al.
Radiother Oncol
. 2022 Apr;
171:69-76.
PMID: 35447283
Background And Purpose: The RAPIDO trial demonstrated a decrease in disease-related treatment failure (DrTF) and an increase in pathological complete responses (pCR) in locally advanced rectal cancer (LARC) patients receiving...
20.
Vliek S, Noordhoek I, Meershoek-Klein Kranenbarg E, van Rossum A, Dezentje V, Jager A, et al.
J Clin Oncol
. 2022 Apr;
40(25):2934-2945.
PMID: 35442755
Purpose: For postmenopausal patients with breast cancer, previous subgroup analyses have shown a modest benefit from adjuvant bisphosphonate treatment. However, the efficacy of oral nitrogen-containing bisphosphonates such as ibandronate is...